Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.09.08 | Nuclear receptors and signalling | ECE2015

Study of a possible interaction between reactive oxygen species and the mTORC1 pathway in the regulation of energy balance

Haissaguerre Magalie , Clark Samantha , Tabarin Antoine , Cota Daniela

Obesity and its consequent metabolic disorders are severe health problems. The mechanistic target of rapamycin complex 1 (mTORC1) pathway is an important hypothalamic integrator of the actions of nutrients and hormones on food intake (FI). Nutrient availability also affects the formation of reactive oxygen species (ROS) in the hypothalamus and regulates neuronal activity. In the present study, we hypothesise that modulation of mTORC1 activity mediates ROS effects on FI. To thi...

ea0056p870 | Pituitary - Clinical | ECE2018

Safety and efficacy of long-acting Pasireotide monotherapy in acromegalic patients treated with a combination of first-generation somatostatin analogs and cabergoline or pegvisomant

Lasolle Helene , Ferriere Amandine , Nunes Marie-Laure , Haissaguerre Magalie , Tabarin Antoine

Introduction: Combination therapy using pegvisomant and cabergoline with first-generation long-acting somatostatin analogs (1GSSA) is a common procedure in acromegalic patients that are not fully controlled by surgery and 1GSSA. Pasireotide-LAR is a new multireceptor-targeted somatostatin receptor ligand that has superior efficacy over octreotide LAR to control GH and IGF1 levels. Little data is available about the efficacy and safety of pasireotide monotherapy in patients tre...

ea0090p547 | Adrenal and Cardiovascular Endocrinology | ECE2023

Safe observation of early recurrence of asymptomatic pheochromocytomas in MEN2 patients

Puerto Marie , Buffet Alexandre , Haissaguerre Magalie , Nunes Marie-Laure , Mathilde Duval , Haythem Najah , Amar Laurence , Tabarin Antoine

Controlateral recurrence of pheochromocytoma is frequent in MEN2 patients. Cortical sparing adrenalectomy is currently recommended in this situation, but conveys a risk of adrenal insufficiency in up to 45 % of patients. The natural history of recurrent pheochromocytome is poorly known. Thus, appropriate timing of surgery and the possibility to postpone safely surgery remain debatable. We report our experience of long-term follow up of non-operated 16 pheochromocytomas in 13 M...

ea0081oc6.3 | Oral Communications 6: Endocrine-Related Cancer | ECE2022

Systematic detection of mosaicism by using digital NGS in a cohort of 119 unresolved MEN1 cases reveals 3 new MEN1 mosaicisms

Lagarde Arnaud , Mougel Gregory , Coppin Lucie , Haissaguerre Magalie , Le Collen Lauriane , Klein Marc , Odou Marie-Francoise , Tabarin Antoine , Brixi Hedia , Delemer Brigitte , Barlier Anne , Romanet Pauline

Context: Mosaicism is a feature of several inherited tumor syndromes but is rarely systematically looked for in routine. MEN1 is an autosomal dominant hereditary syndrome characterized by several endocrine tumors affecting parathyroids, pancreas, and anterior pituitary most of the time, due to inactivating mutations in the MEN1 gene. Few cases of mosaicism in Multiple Endocrine Neoplasia type 1 (MEN1) have been described. MEN1 mosaicism is probably under-diag...

ea0070ep6 | Adrenal and Cardiovascular Endocrinology | ECE2020

References values for midnight serum cortisol

Lauro Cindy , Rigo Marine , Sieuw Aurélie , Georges Agnès , Haissaguerre Magalie , Tabarin Antoine , Brossaud Julie , Corcuff Jean-Benoît

The loss of nychthemeral rhythm is a feature of endogenous hypercorticism that may be investigated by the assay of midnight salivary cortisol (serC0h) although often replaced by serum cortisol assay. However, manufacturers of cortisol immunoassays kits seldom provide reference values for this horary. We present here tentative reference values of serC0h with an automated imunoanalyzer (DXi800, Beckman Coulter).The population retrospe...

ea0081oc7.3 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Clinical practice outcomes from 107 patients with Cushing’s syndrome treated with osilodrostat in France

Dormoy Alexandre , Haissaguerre Magalie , Drui Dephine , Demarquet Lea , Do Cao Christine , Guignat Laurence , Vaillant C , Papegaey Anne-Cecile , Raznik Yves , Bras Maelle Le , Salenave S , Raingeard Isabelle , Tauveron I , Christine Vantyghem Marie , Francois M , Delemer B , Luca Florina , Mayer Anne , Petit Jean-Michel , Baudin Eric , Chanson Philippe , Castinetti Frederic , Raverot Gerald , Chabre Olivier , Tabarin Antoine , Young Jacques

Background: Osilodrostat is a potent oral inhibitor of the adrenal enzymes aldosterone synthase and 11b-hydroxylase and decreases glucocorticoid and mineralocorticoid production and secretion. Phase 2 and 3 studies from the osilodrostat clinical trial programme have demonstrated the drug’s efficacy and safety in patients with Cushing’s disease. Osilodrostat received European Marketing Authorization (MA) for the treatment of Cushing’s syndrome (CS) in adults....

ea0070oc1.6 | Adrenal and Cardiovascular Endocrinology | ECE2020

Modified GRAS score for prognostic classification of adrenocortical carcinoma: an ENSAT multicentre study

Elhassan Yasir , Altieri Barbara , Berhane Sarah , Cook Harriet , Bertherat Jerome , Fragoso Maria , Kastelan Darko , Terzolo Massimo , Calabrese Anna , Berruti Alfredo , Cosentini Deborah , Laganà Marta , Loli Paola , Baudin Eric , Haak Harm , Canu Letizia , Haissaguerre Magalie , Kimpel Otilia , Deeks Jon , Arlt Wiebke , Libé Rossella , Fassnacht Martin , Ronchi Cristina

Background: Adrenocortical carcinoma (ACC) has an aggressive but heterogenous behaviour. ENSAT stage and Ki67 proliferation index are used to predict clinical outcome but are limited in distinguishing patients with best outcome. We aimed to validate the prognostic role of clinical and histopathological parameters alone or combined by applying a previously proposed points-based score (mGRAS, Lippert JCEM 2018) to a large multicentre cohort of ACC patients.<p class="abstext"...

ea0056oc7.4 | Genomic and clinical aspects of endocrine tumours | ECE2018

Germline mutations in the mitochondrial 2-oxoglutarate/malate carrier (SLC25A11) gene confer predisposition to metastatic paragangliomas

Buffet Alexandre , Morin Aurelie , Castro-Vega Luis-Jaime , Habarou Florence , Lussey-Lepoutre Charlotte , Letouze Eric , Lefebvre Herve , Guilhem Isabelle , Haissaguerre Magalie , Raingeard Isabelle , Padilla-Girola Mathilde , Tran Thi , Tchara Lucien , Bertherat Jerome , Amar Laurence , Ottolenghi Chris , Burnichon Nelly , Gimenez-Roqueplo Anne-Paule , Favier Judith

Integrative genomics studies of paragangliomas (PGL) have shown that PGL susceptibility genes are the main drivers of tumorigenesis. Comprehensive genetic analyses have identified germline SDHB and, to a lesser extent, FH gene mutations, as predominant causes of metastatic PGL. However, some suspicious cases remain unexplained. We performed whole-exome sequencing of a paraganglioma exhibiting an SDHx-like molecular profile in the absence of SDHx<...

ea0081yi6 | Young Investigator Awards | ECE2022

Integrated genomics reveals the molecular classification of Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH), correlating with specific profiles of illegitimate receptors expression and identifies KDM1A as the genetic cause of food-dependent Cushing syndrome

Bouys Lucas , Violon Florian , Vaczlavik Anna , Gaetan Giannone , Jouinot Anne , Armignacco Roberta , Cavalcante Isadora Pontes , Berthon Annabel , Letouze Eric , Vaduva Patricia , Barat Maxime , Fideline Bonnet , Perlemoine Karine , Ribes Christopher , Sibony Mathilde , North Marie-Odile , Espiard Stephanie , Haissaguerre Magalie , TAUVERON Igor , Guignat Laurence , Groussin Lionel , Dousset Bertrand , Reincke Martin , Barisson Villares Fragoso Maria Candida , Stratakis Constantine A , Pasmant Eric , Libe Rossella , Assie Guillaume , Ragazzon Bruno , Bertherat Jerome

Introduction: In Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH), cortisol secretion may be consecutive to physiological stimuli, through the illegitimate expression of G-protein coupled receptors (GPCR) in adrenocortical cells. The most characterized is the overexpression of GIP receptor (GIPR) leading to food-dependent Cushing syndrome (FDCS) but it has not been associated with the consecutive inactivation of ARMC5 responsible for 25% of PBMAH. This work aimed to ...

ea0098t5 | Trials In Progress | NANETS2023

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Capdevila Jaume , Fazio Nicola , Alvarez Rosa , Ansquer Catherine , Baldari Sergio , Baudin Eric , Benavent Marta , Benini Lavinia , Beron Amandine , Berruti Alfredo , Cingarlini Sara , del Olmo-Garcia Maribel , Deshayes Emmanuel , Garcia-Alvarez Alejandro , Garcia-Carbonero Rocio , Haissaguerre Magalie , Hernando Jorge , Anido Herranz Urbano , Jimenez-Fonseca Paula , Lepage Come , Llana Belen , Molina-Cerrillo Javier , Panzuto Francesco , Pubul Virginia , Sansovini Maddalena , Tafuto Salvatore , Taieb David , Teule Alex , Versari Annibale , Villacampa Guillermo , Walter Thomas

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...